Rohit Setlem

Rohit Setlem

Auto-generated profile, based on publicly available information

Rohit Setlem

Laboratory of Signaling and Gene Regulation, Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas, Texas

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2022 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
DKDae-Seok Kim
Dae-Seok Kim
CCCristel Camacho
Cristel Camacho
RSRohit Setlem
Rohit Setlem
KKKangsan Kim
Kangsan Kim
SMSrinivas Malladi
Srinivas Malladi
WKW. Lee Kraus
W. Lee Kraus
Long noncoding RNAs have been implicated in many of the hallmarks of cancer. Herein, we found that the expression of lncRNA152 (lnc152; a.k.a. DRAIC), which we annotated previously, is highly upregulated in luminal breast cancer (LBC) and downregulated in triple-negative breast cancer (TNBC). Knockdown of lnc152 promotes cell migration and invasion in LBC cell lines. In contrast, ectopic expression of lnc152 inhibits growth, migration, invasion, and angiogenesis in TNBC cell lines. In mice, lnc152 inhibited the growth of TNBC cell xenografts, as well as metastasis of TNBC cells in an intracardiac injection model. Transcriptome analysis of the xenografts indicated that lnc152 downregulates genes controlling angiogenesis. Using pull down assays followed by LC/MS-MS, we identified RBM47, a known tumor suppressor in breast cancer, as a lnc152-interacting protein. The effects of lnc152 in TNBC cells are mediated, in part, by regulating the expression of RBM47. Collectively, our results demonstrate that lnc152 is an angiogenesis-inhibiting tumor suppressor that attenuates the aggressive cancer-related phenotypes found in TNBC. Implications: This study identifies lncRNA152 as an angiogenesis-inhibiting tumor suppressor that attenuates the aggressive cancer-related phenotypes found in TNBC by upregulating the expression of the tumor suppressor RBM47. As such, lncRNA152 may serve as a biomarker to track aggressiveness of breast cancer, as well as therapeutic target for treating TNBC.

3 April 2023
Verified
Other
Open access
DKDae-Seok Kim
Dae-Seok Kim
CCCristel Camacho
Cristel Camacho
RSRohit Setlem
Rohit Setlem
KKKangsan Kim
Kangsan Kim
SMSrinivas Malladi
Srinivas Malladi
WKW. Lee Kraus
W. Lee Kraus
Supplementary Table from Functional Characterization of lncRNA152 as an Angiogenesis-Inhibiting Tumor Suppressor in Triple-Negative Breast Cancers

3 April 2023
Verified
Other
Open access
DKDae-Seok Kim
Dae-Seok Kim
CCCristel Camacho
Cristel Camacho
RSRohit Setlem
Rohit Setlem
KKKangsan Kim
Kangsan Kim
SMSrinivas Malladi
Srinivas Malladi
WKW. Lee Kraus
W. Lee Kraus
Supplementary Table from Functional Characterization of lncRNA152 as an Angiogenesis-Inhibiting Tumor Suppressor in Triple-Negative Breast Cancers

3 April 2023
Verified
Other
Open access
DKDae-Seok Kim
Dae-Seok Kim
CCCristel Camacho
Cristel Camacho
RSRohit Setlem
Rohit Setlem
KKKangsan Kim
Kangsan Kim
SMSrinivas Malladi
Srinivas Malladi
WKW. Lee Kraus
W. Lee Kraus
Supplementary Figure from Functional Characterization of lncRNA152 as an Angiogenesis-Inhibiting Tumor Suppressor in Triple-Negative Breast Cancers

3 April 2023
Verified
Other
Open access
DKDae-Seok Kim
Dae-Seok Kim
CCCristel Camacho
Cristel Camacho
RSRohit Setlem
Rohit Setlem
KKKangsan Kim
Kangsan Kim
SMSrinivas Malladi
Srinivas Malladi
WKW. Lee Kraus
W. Lee Kraus
Long noncoding RNAs have been implicated in many of the hallmarks of cancer. Herein, we found that the expression of lncRNA152 (lnc152; a.k.a. DRAIC), which we annotated previously, is highly upregulated in luminal breast cancer (LBC) and downregulated in triple-negative breast cancer (TNBC). Knockdown of lnc152 promotes cell migration and invasion in LBC cell lines. In contrast, ectopic expression of lnc152 inhibits growth, migration, invasion, and angiogenesis in TNBC cell lines. In mice, lnc152 inhibited the growth of TNBC cell xenografts, as well as metastasis of TNBC cells in an intracardiac injection model. Transcriptome analysis of the xenografts indicated that lnc152 downregulates genes controlling angiogenesis. Using pull down assays followed by LC/MS-MS, we identified RBM47, a known tumor suppressor in breast cancer, as a lnc152-interacting protein. The effects of lnc152 in TNBC cells are mediated, in part, by regulating the expression of RBM47. Collectively, our results demonstrate that lnc152 is an angiogenesis-inhibiting tumor suppressor that attenuates the aggressive cancer-related phenotypes found in TNBC.Implications:This study identifies lncRNA152 as an angiogenesis-inhibiting tumor suppressor that attenuates the aggressive cancer-related phenotypes found in TNBC by upregulating the expression of the tumor suppressor RBM47. As such, lncRNA152 may serve as a biomarker to track aggressiveness of breast cancer, as well as therapeutic target for treating TNBC.

3 April 2023
Verified
Other
Open access
DKDae-Seok Kim
Dae-Seok Kim
CCCristel Camacho
Cristel Camacho
RSRohit Setlem
Rohit Setlem
KKKangsan Kim
Kangsan Kim
SMSrinivas Malladi
Srinivas Malladi
WKW. Lee Kraus
W. Lee Kraus
Supplementary Table from Functional Characterization of lncRNA152 as an Angiogenesis-Inhibiting Tumor Suppressor in Triple-Negative Breast Cancers